Marcoumar (Phenprocoumon)

Phenprocoumon is used as an oral anticoagulant to manage conditions associated with abnormal blood clot formation.

• Thromboembolic disorders: reduces risk of clot formation and recurrence.
• Atrial fibrillation: prevents stroke and systemic embolism in patients with non‑valvular atrial fibrillation.
• Orthopedic surgery: lowers incidence of venous thromboembolism following hip or knee replacement procedures.

• Phenprocoumon exerts its anticoagulant effect by inhibiting the enzyme vitamin K epoxide reductase (VKOR). This blockade prevents the regeneration of reduced vitamin K, a cofactor required for γ‑carboxylation of clotting factors II, VII, IX and X in the liver. Consequently, the synthesis of these vitamin K‑dependent clotting proteins is reduced, leading to prolonged coagulation times and decreased thrombus formation.

Phenprocoumon may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Minor bleeding: bruising, gum bleeding, or epistaxis.
• Gastrointestinal discomfort: nausea, abdominal pain, or dyspepsia.
• Skin reactions: rash or mild itching.

Serious or Rare Side Effects

• Major hemorrhage: intracranial, gastrointestinal or severe internal bleeding.
• Skin necrosis: painful, purplish skin lesions that may progress.
• Allergic reactions: anaphylaxis, angioedema, or severe urticaria.
• Hepatotoxicity: elevated liver enzymes or liver injury (rare).

When prescribing phenprocoumon, clinicians should observe several safety measures to minimize bleeding risk and ensure therapeutic effectiveness.

• Baseline assessment: obtain complete blood count and coagulation profile before initiation.
• Dose adjustment: monitor INR regularly and adjust dose to maintain target therapeutic range.
• Drug interactions: review concomitant medications that affect vitamin K metabolism or platelet function.
• Patient education: advise avoidance of activities with high injury risk and inform about signs of bleeding.
• Liver or kidney impairment: use caution and consider dose modification in patients with hepatic or renal dysfunction.
• Store at ambient temperature: keep tablets in original container, protect from moisture and direct sunlight.

Phenprocoumon interacts with several medicines that can alter its anticoagulant effect.

Major Interactions (Avoid)

• Strong CYP2C9 inhibitors: amiodarone, fluconazole, or other potent inhibitors may markedly increase INR.
• Antiplatelet agents: aspirin, clopidogrel can amplify bleeding risk.
• Non‑steroidal anti‑inflammatory drugs (NSAIDs): ibuprofen, naproxen may potentiate hemorrhage.

Moderate Interactions (Monitor Closely)

• Vitamin K‑rich foods or supplements: leafy greens, warfarin‑containing herbal products can reduce efficacy.
• Antibiotics affecting gut flora: broad‑spectrum agents like rifampin may lower INR.
• Heparin or low‑molecular‑weight heparin: concurrent use requires careful coagulation monitoring.